Compare FTHM & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | NMTC |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 29.2M |
| IPO Year | 2020 | 2010 |
| Metric | FTHM | NMTC |
|---|---|---|
| Price | $0.95 | $2.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $11.90 |
| AVG Volume (30 Days) | ★ 4.5M | 25.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.71 | ★ 80.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | $9,097,692.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.45 | ★ 163.47 |
| 52 Week Low | $0.40 | $0.55 |
| 52 Week High | $3.37 | $5.40 |
| Indicator | FTHM | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 31.68 |
| Support Level | $0.89 | $0.67 |
| Resistance Level | $1.27 | $3.41 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.29 | 25.44 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.